DelveInsight’s, “RNA Interference Therapy Competitive Landscape 2023” report provides comprehensive insights about 40+ RNA Interference Therapy companies and 90+ drugs in RNA Interference Therapy Competitive landscape. It covers the RNA Interference Therapy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive RNA Interference Therapy pipeline products in this space.

 

Key takeaways from the RNA Interference Therapy Report

• DelveInsight’s RNA Interference Therapy report depicts a robust space with 40+ RNA Interference Therapy companies working to develop 90+ pipeline therapies for RNA Interference Therapy treatment.
• The leading RNA Interference Therapy companies working in the market include Silence Therapeutics, Janssen Research & Development, Eli Lilly and Company, Arrowhead Pharmaceuticals, Sylentis, Sirnaomics, Dicerna Pharmaceuticals, Suzhou Ribo Life Science, Alnylam Pharmaceuticals, Suzhou Ribo Life Science, Vir Biotechnology, Arbutus Biopharma, Silenseed, OliX Pharmaceuticals, Bio-Path Holdings, and others.
• Promising RNA Interference Therapy Therapies in the various stages of development include patisiran (ALN-TTR02), Sterile Normal Saline (0.9% NaCl), ALN-TTRSC (revusiran) for subcutaneous administration, Patisiran, ALN-PCSSC, Lumasiran, Fitusiran (SAR439774), and others.
• December 2023: Alnylam Pharmaceuticals announced a study of Phase 1 clinical trials for ALN-HSD. The purpose of this study is to evaluate the safety and tolerability of single ascending doses of ALN-HSD in healthy participants (Part A) and multiple doses of ALN-HSD in patients with NASH (Parts B and C).
• March 2023: Alnylam Pharmaceuticals Inc., the leading RNAi therapeutics company, and Medison Pharma, a global pharma company focused on providing access to highly innovative therapies for patients in international markets, announced an expansion of their existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary, Slovakia, Lithuania, Estonia and Latvia, in addition to Israel.

 

Request a sample and discover the recent advances in RNA Interference Therapy Drugs @ RNA Interference Therapy Competitive Landscape Report

 

The RNA Interference Therapy report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the RNA Interference Therapy report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

 

RNA Interference Therapy Overview

RNA interference (RNAi) is one of the pathways, collectively named RNA silencing pathways that employ small RNAs as guides for sequence-specific silencing. RNAi was discovered in C. elegans and defined as sequence-specific mRNA degradation induced by long double-stranded RNA (dsRNA). The RNA interference (RNAi) pathway regulates mRNA stability and translation in nearly all human cells.

 

Find out more about RNA Interference Therapy Analytical Perspective: In-depth Commercial Assessment @ RNA Interference Therapy Collaboration Analysis by Companies

 

RNA Interference Therapy Companies and Therapies

• Biogen/Ionis Pharmaceuticals: Nusinersen
• Novartis AG: Leqvio
• Alnylam Pharmaceuticals Inc.: Cemdisiran
• Arrowhead Pharmaceuticals Inc.: ARO-APOC3
• Vir Biotechnology: VIR-2218
• Akamis Bio: AB-729

 

RNA Interference Therapy Competitive Landscape

The RNA Interference Therapy report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

 

RNA Interference Therapy Report Assessment

• Company Analysis
• RNA Interference Therapy Therapeutic Assessment
• RNA Interference Therapy Pipeline Assessment
• Inactive RNA Interference Therapy drugs assessment
• RNA Interference Therapy Unmet Needs

 

Learn more about the emerging RNA Interference Therapy Competitive Landscape @ RNA Interference Therapy Market Drivers and Barriers, Unmet Needs

 

Scope of the RNA Interference Therapy Report

• Coverage- Global
• RNA Interference Therapy Companies- Therapeutics, Janssen Research & Development, Eli Lilly and Company, Arrowhead Pharmaceuticals, Sylentis, Sirnaomics, Dicerna Pharmaceuticals, Suzhou Ribo Life Science, Alnylam Pharmaceuticals, Suzhou Ribo Life Science, Vir Biotechnology, Arbutus Biopharma, Silenseed, OliX Pharmaceuticals, Bio-Path Holdings, and others.
• RNA Interference Therapy Therapies- patisiran (ALN-TTR02), Sterile Normal Saline (0.9% NaCl), ALN-TTRSC (revusiran) for subcutaneous administration, Patisiran, ALN-PCSSC, Lumasiran, Fitusiran (SAR439774), and others.
• RNA Interference Therapy Therapeutics Assessment- Product Type, Stage and Product Type, Route of Administration, Stage and Route of Administration, Molecule Type, Stage and Molecule Type

 

Dive deep into rich insights for new drugs for RNA Interference Therapy Product Developmental Activities, Visit @ RNA Interference Therapy Research and Development Activities

 

Table of Content

1. Introduction
2. RNA Interference Therapy Executive Summary
3. RNA Interference Therapy: Overview
4. RNA Interference Therapy -Analytical Perspective: In-depth Commercial Assessment
5. RNA Interference Therapy Competitive Landscape
6. RNA Interference Therapy Therapeutic Assessment
7. RNA Interference Therapy: Company and Product Profiles (Marketed Therapies)
8. Daiichi Sankyo
9. DELYTACT
10. RNA Interference Therapy: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Phase III)
12. Alnylam Pharmaceuticals
13. Cemdisiran
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. Vir Biotechnology
17. VIR-2218
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. Company Name
21. Product Name
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. Company Name
25. Product Name
26. Drug profiles in the detailed report…..
27. Inactive Products
28. RNA Interference Therapy Unmet needs
29. RNA Interference Therapy Market drivers and barriers
30. Appendix

 

For further information on the RNA Interference Therapy Report @ RNA Interference Therapy Preclinical and Discovery Stage Products

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services